首页> 外文期刊>Hormone and Metabolic Research >Risk Factors of Hyperthyroidism with Hepatic Function Injury: A 4-Year Retrospective Study
【24h】

Risk Factors of Hyperthyroidism with Hepatic Function Injury: A 4-Year Retrospective Study

机译:甲状腺功能亢进症伴肝功能损伤的危险因素:4年回顾性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatic function injury is one of the common complications of hyperthyroidism (mainly Graves' disease), which affects the choice of treatment and the curative rate. Our goal was to describe clinical and biochemical patterns in patients suffering from Graves' disease (GD) and hepatic function injury and to determine the influential factors. A cohort of 1 070 patients who received I-131 treatment were studied. Many examinations were performed before I-131 therapy, such as: the 24-h radioactive iodine uptake of thyroid (RAIU(24 h)) and serum-free triiodothyronine (FT3), free thyroxine (FT4), sensitive thyroid-stimulating hormone (sTSH), antithyrotrophin receptor antibody (TRAb), thyroglobulin antibody (TgAb), and antithyroid peroxidase antibody (TPOAb), serum hepatic function tests, etc. Data were analyzed by the unpaired t-test, the independent samples t-test, the chi(2) test, logistic regression, and Pearson bivariate correlation. Age, course of GD, thyroid's weight, FT4, TPOAb, and TRAb in GD patients with hepatic function injury were higher than those with normal hepatic function patients. The influential factors were age, hyperthyroidism duration, heart rate, thyroid's weight, FT4, RAIU(24 h), TgAb, TPOAb, and TRAb. RAIU(24 h) was the protecting factor. Age, course of GD, heart rate, thyroid's weight, FT4, TRAb, and TPOAb were the risk factors. Patients whose age was higher than 45 years old, heart rate above 90 bpm, thyroid weight more than 35 g, the hyperthyroidism duration more than 3 years, FT4 higher than 70.5 pmol/l, the level of TPOAb above 360 IU/ml, and the level of TRAb above 15 IU/l have increased risk of hepatic function injury. As treatment I-131 therapy was found to be the best choice.
机译:肝功能损伤是甲状腺功能亢进症(主要是格雷夫斯病)的常见并发症之一,它会影响治疗的选择和治愈率。我们的目标是描述患有Graves病(GD)和肝功能损伤的患者的临床和生化模式,并确定影响因素。研究了接受I-131治疗的1070名患者。在I-131治疗之前进行了许多检查,例如:甲状腺24小时放射性碘摄取(RAIU(24 h))和无血清三碘甲状腺素(FT3),游离甲状腺素(FT4),敏感的促甲状腺激素( sTSH),抗甲状腺素受体抗体(TRAb),甲状腺球蛋白抗体(TgAb)和抗甲状腺过氧化物酶抗体(TPOAb),血清肝功能测试等。数据通过未配对t检验,独立样本t检验,chi (2)检验,逻辑回归和Pearson双变量相关。肝功能损伤的GD患者的年龄,GD病程,甲状腺重量,FT4,TPOAb和TRAb均高于正常肝功能患者。影响因素是年龄,甲亢持续时间,心率,甲状腺重量,FT4,RAIU(24 h),TgAb,TPOAb和TRAb。 RAIU(24 h)是保护因子。年龄,GD病程,心率,甲状腺重量,FT4,TRAb和TPOAb是危险因素。年龄大于45岁,心率大于90 bpm,甲状腺重量大于35 g,甲亢持续时间大于3年,FT4大于70.5 pmol / l,TPOAb大于360 IU / ml的患者以及高于15 IU / l的TRAb水平会增加肝功能损伤的风险。作为治疗方法,I-131治疗被认为是最佳选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号